Drug-induced liver diseases

Journal of Hepatology

Volumn 32, Issue SUPPL.1, 2000, Pages 77-88

  Larrey, Dominique ^a  

^a HÔPITAL SAINT ELOI   (France)

Author keywords

Drug induced hepatotoxicity; Herbal medicines

Indexed keywords

AJMALINE; AMOXICILLIN PLUS CLAVULANIC ACID; ANDROGEN; AZATHIOPRINE; BETA LACTAM ANTIBIOTIC; CARBAMAZEPINE; CYTARABINE; DEXTROPROPOXYPHENE; DIDANOSINE; DRUG; ERYTHROMYCIN; ESTROGEN; FLUOXETINE; GOLD SALT; HALOTHANE; INDINAVIR; IPRONIAZID; ISONIAZID; KETOCONAZOLE; MACROLIDE; PARACETAMOL; PAROXETINE; PHENOTHIAZINE DERIVATIVE; PYRAZINAMIDE; RILUZOLE; RITONAVIR; SAQUINAVIR; SERTRALINE; STAVUDINE; SULFONAMIDE; TACRINE; TAMOXIFEN; TERBINAFINE; TOLCAPONE; TOPIRAMATE; TROLEANDOMYCIN; UNINDEXED DRUG; VALPROIC ACID; ZALCITABINE; ZIDOVUDINE;

ADULT; AGE; ALCOHOL ABUSE; CHILD; CHOLANGITIS; CHOLESTASIS; CHOLESTATIC HEPATITIS; DRUG INDUCED DISEASE; DRUG TOXICITY; FEMALE; GENDER; GENETIC DISORDER; HEPATITIS; HUMAN; LIVER DISEASE; LIVER INJURY; LIVER TOXICITY; MALE; NUTRITION; PREGNANCY; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ANIMALS; BIOPSY; DRUG EVALUATION, PRECLINICAL; FRANCE; HUMANS; LIVER; LIVER DISEASES; PREVALENCE;

EID: 0034051526     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0168-8278(00)80417-1     Document Type: Article

References (53)

1. Tanguy G, Bernard V, Hyrailles V, Gosp AM, Veyrac M, Larrey D. Iatrogenic disorders inducing hospital admission. A prospective study in a hospital gastrointestinal department. 7th United European Gastroenterology Week, 13-7 Nov 1999, Rome.
2. Stricker BHCH. Drug-induced Hepatic Injury. 2nd edn. Amsterdam: Elsevier; 1992.
3. Farrell GC. Drug-induced liver disease. London: Churchill Livingstone; 1994.
4. Pessayre D, Larrey D, Biour M. Drug-induced liver injury. In: Bircher J, Benhamou JP, McIntyre N, Rizzetto M, Rodés J, editors. Oxford Textbook of Clinical Hepatology, 2nd edn, Vol. 2. Oxford: Oxford University Press; 1999. p. 1261-315.
5. Biour M, Poupon R, Grangé J-D, Chazouillères O, Jaillon P. Hépatotoxicité des médicaments. Gastroenterol Clin Biol; 22: 1004-44.
6. Zimmerman HJ. Hepatotoxicity. New York: Appleton-CenturyCrofts; 1978.
7. Larrey D. Hepatotoxicity of herbal medicine. J Hepatol 1997; 26 (suppl 1): 47-51.
8. Negro F, Mondardini A, Palmas F. Hepatotoxicity of saccharin. N Engl J Med 1994; 331: 134-5.
9. Larrey D. Hépatites médicamenteuses: aspects épidémiologiques, cliniques, diagnostiques, et physiopathologiques en 1995. Rev Med Int 1995; 16: 752-8.
10. Jean-Pastor MJ, Jouglard J. Bilan des accidents hépatiques médicamenteux recueillis par la pharmacovigilance française. Thérapie 1984; 39: 493-500.
11. Dossing M, Andreasen BP. Drug-induced liver disease in Denmark. An analysis of 572 cases of hepatotoxicity reported to the Danish board of adverse reaction to drugs. Scand J Gastroenterol 1982; 17: 205-11.
12. Bernuau J, Benhamou JP. Fulminant and subfulminant liver failure. In: Bircher J, Benhamou JP, McIntyre N, Rizzetto M, Rodés J, editors. Oxford Textbook of Clinical Hepatology, 2nd edn, Vol. 2. Oxford: Oxford University Press; 1999. p. 1341-72.
13. Takahashi Y, Okuda K. Fulminant hepatitis in Japan: etiology and prognostic prediction. Chin J Gastroenterol 1993; 10: 337-50.
14. Pessayre D, Larrey D. Mechanisms of drug-induced hepatitis. In: Guillouzo A, editor. Liver Cells and Drugs. Vol. 164. Colloque INSERM/John Libbey Eurotext Ltd.; 1988. p. 129-42.
15. Dansette PM, Bonierbale E, Minoletti C, Beaune PH, Pessayre D, Mansuy D. Drug-induced immunotoxicity. Eur J Drug Metab Pharmacokinct 1998; 23: 443-51.
16. Homberg JC, Abuaf N, Helmy-Khalil S, Biour M, Poupon R, Islam S, et al. Drug-induced hepatitis associated with antiintracytoplasmic organelle autoantibodies. Hepatology 1887; 7: 1333-9.
17. Bourdi M, Larrey D, Nataf J, Bernuau J, Pessayre D, Iwasaki M, et al. Anti-liver endoplasmic reticulum autoantibodies are directed against human cytochrome P-450 IA2: a specific marker of dihydralazine-induced hepatitis. J Clin Invest 1990; 85: 1967 73.
18. Beaune PH, Dansette PM, Mansuy D, Kiffel L, Finck M, Amar C, et al. Human anti-endoplasmic reticulum auto-antibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug. Proc Natl Acad Sci USA 1987; 84: 551-5.
19. Bourdi M, Chen WQ, Peter RM, Martin JL, Buters JTM, Nelson SD, et al. Human cytochrome P-450 2E1 is a major autoantigen associated with halothane hepatitis. Chem Res Toxicol 1996; 9: 1159-66.
20. Eliasson E, Kenna JG. Cytochrome P-450 2E1 is a cell surface autoantigen in halothane hepatitis. Mol Pharmacol 1996; 50: 573-82.
21. Fromenty B, Pessayre D. Impaired mitochondrial function in microvesicular steatosis. Effects of drugs, ethanol, hormones and cytokincs. J Hepatol 1997; 26: 43-53.
22. Larrey D, Pageaux GP. Genetic predisposition to drug-induced hepatotoxicity. J Hepatol 1997; 26: 12-21.
23. Larrey D, Lettéron P, Foliot A, Descatoire V, Degott C, Genève J, et al. Effects of pregnancy on the toxicity and metabolism of acetaminophen in mice. J Pharmacol Exp Ther 1986; 237: 283-91.
24. Morgan MY, Reshef R, Shah RR, Oates NS, Smith RL, Sherlock S. Impaired oxidation of debrisoquine in patients with perhexiline liver injury. Gut 1984; 25: 1057-64.
25. Larrey D, Amouyal G, Tinel M, Lettéron P, Berson A, Labbe G, et al. Polymorphism of dextromethorphan oxidation in a French population. Br J Clin Pharmacol 1987; 24: 676-9.
26. Gonzales FJ, Idle JR. Pharmacogenetic phenotyping and genotyping. Present status and future potential. Clin Pharmacokinet 1994; 26: 59-70.
27. Larrey D, Tinel M, Amouyal G, Fréneaux E, Berson A, Fouin-Fortunet H, et al. Genetically determined oxidation polymorphism and drug hepatotoxicity. Study of 51 patients. J Hepatol 1989; 8: 158-64.
28. Horsmans Y, Lannes D, Pessayre D, Larrey D. Possible association between poor metabolism of mephenytoin and hepatotoxicity caused by Atrium®. A fixed combination preparation containing phenobarbital, febarbamate and difebarbamate. J Hepatol 1994; 21: 1075 9.
29. De Morais SMF, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994; 269: 15419-52.
30. Spielberg SP. In vitro assessment of pharmacogenetic susceptibility to toxic drug metabolites in humans. Fed Proc 1984; 43: 2308-13.
31. Larrey D, Berson A, Hebersetzer F, Tinel M, Cstot A, Babany G, et al. Genetic predisposition to drug hepatotoxicity. Role in hepatitis causes by amineptine, a tricyclic antidepressant. Hepatology 1989; 10: 168-73.
32. Deloménie C, Mathelier-Fusade P, Longuemaux S, Rozenbaum W, Leynadier F, Krishnamoorthy R, et al. Glutathione S-transferase (GSTM1) null genotype and sulphonamide intolerance in acquired immunodeficiency syndrome. Pharmacogenetics 1997; 7: 519-20.
33. De Sousa M, Pirmohamed M, Kitteringham NR, Woolf T, Park BK. No association between tacrine transaminitis and the glutathione transferase θ genotype in patients with Alzheimer's disease. Pharmacogenetics 1998; 8: 353-5.
34. Berson A, Fréneaux E, Larrey D, Lepage V, Douay C, Mallet C, et al. Possible role of HLA in hepatotoxicity. An exploratory study in 71 patients with drug-induced idiosyncratic hepatitis. J Hepatol 1994; 20: 336-42.
35. Criteria of drug-induced liver disorders. Report of an International Consensus Meeting. J Hepatol 1990; 11: 272-6.
36. Zimmerman HJ, Lewis JH. Drug-induced cholestasis. Med Toxicol 1987; 2: 112.
37. Larrey D, Erlinger S. Drug-induced cholestasis. Bailliere's Clin Gastroenterol 1988; 2: 423-52.
38. Larrey D, Pessayre D, Duhamel G. Prolonged cholestatic jaundice after ajmaline-induced acute hepatitis. J Hepatol 1986; 2: 81-7.
39. Degott C, Feldmann G, Larrey D, Durand-Schneider AM, Grangé D, Machyekhi JP, et al. Drug-induced prolonged cholestasis in adults: a histological semiquantitative study demonstrating progressive ductopenia. Hepatology 1992; 17: 244-51.
40. Larrey D, Michel H. Pathologie biliaire due aux médicaments. Gastroenterol Clin Biol 1993; 17: 59-H65.
41. O'Grady JG. Paracetamol-induced acute liver failure: prevention and management. J Hepatol 1997; 26: 41-6.
42. Ioannides C. Cytochromes P450. Metabolic and toxicological aspects. Boca Raton: CRC Press; 1996.
43. Maurel P. Drug-metabolizing enzymes. Curr Opin Crit Care 1998; 4: 213-8.
44. Remy AJ, Camu W, Ramos J, Blanc P, Larrey D. Acute hepatitis after riluzole administration. J Hepatol 1999; 30: 527-30.
45. Mansuy D. Molecular structure and hepatotoxicity: compared data about two closely related thiophene compounds. J Hepatol 1997; 26: 22-5.
46. Fau D, Mounia L, Farrell G, Moreau A, Moulis C, Feldmann G, et al. Diterpenoids from germander, an herbal medicine, induce apoptosis in isolated rat hepatocytes. Gastroenterology 1997; 113: 1334-46.
47. Remy AJ, Larrey D, Pageaux GP, Ribstein J, Ramos J, Michel H. Cross hepatotoxicity between tricyclic antidepressants and phenothiazines. Eur J Gastroenterol Hepatol 1995; 7: 373-6.
48. Larrey D, Tinel M, Lettéron P, Maurel P, Loeper J, Belghiti J, et al. Metabolic activation of the new tricyclic antidepressant tianeptine by human liver cytochrome P-450. Biochem Pharmacol 1990; 14: 504-6.
49. Fromenty B, Fréneaux E, Labbe G, Deschamps D, Larrey D, Lettéron P, et al. Tianeptine, a new tricyclic antidepressant metabolized by β-oxidation of its heptanoic side chain, inhibits the mitochondrial oxidation of medium and short chain fatty acids in mice. Biochem Pharmacol 1989; 38: 3743-51.
50. Le Bricquir Y, Larrey D, Blanc P, Pageaux GP, Michel H. Tianeptine - an instance of drug-induced hepatotoxicity predicted by prospective experimental studies. J Hepatol 1994; 21: 771-3.
51. Guillouzo A, Morel F, Langouêt S, Maheo K, Rissel M. Use of hepatocyte cultures for the study of hepatotoxic compounds. J Hepatol 1997; 26: 73-80.
52. Pompon D, Gautier J-C, Perret A, Truan G, Urban P. Simulation of human xenobiotic metabolism in microorganisms: yeast a good compromise between E. coli and human cells. J Hepatol 1997; 26: 81-5.
53. Ballet F. Hepatotoxicity in drug development: detection, significance and solutions. J Hepatol 1997; 26: 26-36.